glp 1 agonist new GLP-1 agonists approved for clinical use. GLP-1 agonists are available Mechanisms of GLP-1 Receptor Agonist-Induced
Description
The mechanism of action is very imbalanced, since while it has a comparable GIP receptor binding affinity to native GIP, the affinity to the native GLP-1 receptor is five times lower [20, 21]

doi: 10.1097/GOX.0000000000005427 110 DeFronzoRAOkersonTViswanathanPGuanXHolcombeJHMacConellL

Wegovy is licensed in the UK in doses up to 2.4mg for weight loss and, on 14 September 2025, Novo Nordisk published results of a phase IIIb clinical trial (STEP UP, NCT05646706) of a 7.2mg dose of semaglutide for subcutaneous injection 1

April 4, 2025

Henkel, I

Bloomberg (2023)
